跳至主要内容
临床试验/NCT07203690
NCT07203690尚未招募不适用

Development and Application of AI-Based Therapeutic Strategies for Esophageal Cancer Integrating Multimodal Imaging and Digital Pathology

Henan Cancer Hospital0 个研究点目标入组 7,000 人开始时间: 2025年12月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
7,000
主要终点
Pathological Complete Response (pCR) Rate

研究概览

简要总结

The purpose of this clinical study is to conduct a multi-center, big data study to create a neural network decision model for predicting treatment efficacy and prognosis based on multi-modal, multi-temporal imaging features combined with tumor microenvironment scores. It will also use various model interpretation techniques to clarify the role and mechanism of key biomarkers or strongly associated biomarker groups in treatment efficacy and prognosis. Ultimately, it aims to achieve the research and application of AI treatment strategies combining multi-modal imaging and digital pathology to guide clinicians in the personalized treatment strategies for patients with esophageal squamous cell carcinoma.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged 18-70 years;
  • Histologically confirmed esophageal carcinoma by biopsy;
  • No prior antitumor therapy received.

排除标准

  • Contraindications to MRI examination;
  • Poor compliance with antitumor therapy;
  • Unwillingness to participate in the study;
  • Image quality inadequate for diagnostic requirements.

结局指标

主要结局

Pathological Complete Response (pCR) Rate

时间窗: January 2025 - December 2027

The proportion of patients achieving pathological complete response (ypT0 ypN0) after neoadjuvant therapy.

Overall Survival (OS)

时间窗: January 2025 - December 2027

The time from treatment initiation to death from any cause.

Event-Free Survival (EFS)

时间窗: January 2025 - December 2027

The time from treatment initiation to disease progression, recurrence, new primary cancer, or death.

Disease-Free Survival (DFS)

时间窗: January 2025 - December 2027

The time from curative-intent surgery to disease recurrence or death.

次要结局

未报告次要终点

研究者

申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Qujinrong

Clinical Professor

Henan Cancer Hospital

相似试验